- Home
- IBCP vs YMAB Comparison
IBCP vs YMAB Comparison
Compare IBCP & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- YMAB
- Stock Information
- Founded
- IBCP 1864
- YMAB 2015
- Country
- IBCP United States
- YMAB United States
- Employees
- IBCP N/A
- YMAB N/A
- Industry
- IBCP Major Banks
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- YMAB Health Care
- Exchange
- IBCP Nasdaq
- YMAB Nasdaq
- Market Cap
- IBCP 682.1M
- YMAB 631.1M
- IPO Year
- IBCP N/A
- YMAB 2018
- Fundamental
- Price
- IBCP $34.94
- YMAB $14.20
- Analyst Decision
- IBCP Hold
- YMAB Strong Buy
- Analyst Count
- IBCP 3
- YMAB 8
- Target Price
- IBCP $32.17
- YMAB $21.38
- AVG Volume (30 Days)
- IBCP 107.0K
- YMAB 229.5K
- Earning Date
- IBCP 10-24-2024
- YMAB 11-11-2024
- Dividend Yield
- IBCP 2.77%
- YMAB N/A
- EPS Growth
- IBCP 10.27
- YMAB N/A
- EPS
- IBCP 3.12
- YMAB N/A
- Revenue
- IBCP $212,026,000.00
- YMAB $86,546,000.00
- Revenue This Year
- IBCP N/A
- YMAB $11.00
- Revenue Next Year
- IBCP $5.07
- YMAB $19.38
- P/E Ratio
- IBCP $11.10
- YMAB N/A
- Revenue Growth
- IBCP 5.18
- YMAB 1.84
- 52 Week Low
- IBCP $16.90
- YMAB $4.69
- 52 Week High
- IBCP $35.97
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- IBCP 63.41
- YMAB 53.95
- Support Level
- IBCP $33.28
- YMAB $14.04
- Resistance Level
- IBCP $35.08
- YMAB $15.10
- Average True Range (ATR)
- IBCP 0.98
- YMAB 0.72
- MACD
- IBCP 0.29
- YMAB 0.06
- Stochastic Oscillator
- IBCP 96.61
- YMAB 62.34
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.